Recombinant viruses as tools to study human cytomegalovirus immune modulation

Medical Microbiology and Immunology

Volumn 197, Issue 2, 2008, Pages 215-222

  Besold, Katrin ^a   Plachter, Bodo ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Cytomegalovirus; IE1; Immune evasion; Immune modulation; pp65

Indexed keywords

GAMMA INTERFERON; IE1 PROTEIN; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; VIRUS PROTEIN;

CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOMODULATION; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION; VIRUS MUTANT; VIRUS RECOMBINANT;

CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; HUMANS; MUTATION; VIRAL PROTEINS;

EID: 42249114002     PISSN: 03008584     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00430-008-0083-4     Document Type: Review

References (38)

1. Jones TR, Hanson LK, Sun L, Slater JS, Stenberg RM, Campbell AE (1995) Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains. J Virol 69:4830-4841
2. Reddehase MJ (2002) Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat Rev Immunol 2:831-844
3. Plachter B (1999) Immune evasion during cytomegalovirus infection. Biomed Progr 12:71-74
4. Reddehase MJ, Mutter W, Münch K, Bühring HJ, Koszinowski UH (1987) CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol 61:3102-3108
5. Steffens HP, Kurz S, Holtappels R, Reddehase MJ (1998) Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence. J Virol 72:1797-1804
6. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238-241
7. Lin A, Xu H, Yan W (2007) Modulation of HLA expression in human cytomegalovirus immune evasion. Cell Mol Immunol 4:91-98
8. Mocarski ES, Shenk T, Pass RF (2007) Cytomegaloviruses In: Knipe DM, Howley PM (eds) Fields virology. Lippincott Williams & Wilkins, Philadelphia, pp 2701-2772
9. Lilley BN, Ploegh HL (2005) Viral modulation of antigen presentation: manipulation of cellular targets in the ER and beyond. Immunol Rev 207:126-144
10. Pinto AK, Munks MW, Koszinowski UH, Hill AB (2006) Coordinated function of murine cytomegalovirus genes completely inhibits CTL lysis. J Immunol 177:3225-3234
11. Pinto AK, Hill AB (2005) Viral interference with antigen presentation to CD8+ T cells: lessons from cytomegalovirus. Viral Immunol 18:434-444
12. Holtappels R, Gillert-Marien D, Thomas D, Podlech J, Deegen P, Herter S, Oehrlein-Karpi SA, Strand D, Wagner M, Reddehase MJ (2006) Cytomegalovirus encodes a positive regulator of antigen presentation. J Virol 80:7613-7624
13. Wagner M, Gutermann A, Podlech J, Reddehase MJ, Koszinowski UH (2002) Major histocompatibility complex class I allele-specific cooperative and competitive interactions between immune evasion proteins of cytomegalovirus. J Exp Med 196:805-816
14. Manley TJ, Luy L, Jones T, Boeckh M, Mutimer H, Riddell SR (2004) Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection. Blood 104:1075-1082
15. Khan N, Bruton R, Taylor GS, Cobbold M, Jones TR, Rickinson AB, Moss PA (2005) Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2-US11 region or modified vaccinia virus Ankara expressing individual viral genes. J Virol 79:2869-2879
16. Besold K, Frankenberg N, Pepperl-Klindworth S, Kuball J, Theobald M, Hahn G, Plachter B (2007) Processing and MHC class I presentation of human cytomegalovirus pp65-derived peptides persist despite gpUS2-11-mediated immune evasion. J Gen Virol 88:1429-1439
17. Borst EM, Hahn G, Koszinowski UH, Messerle M (1999) Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol 73:8320-8329
18. Gutermann A, Bubeck A, Wagner M, Reusch U, Menard C, Koszinowski UH (2002) Strategies for the identification and analysis of viral immune-evasive genes: cytomegalovirus as an example. Curr Top Microbiol Immunol 269:1-22
19. Falk CS, Mach M, Schendel DJ, Weiss EH, Hilgert I, Hahn G (2002) NK cell activity during human cytomegalovirus infection is dominated by US2-11-mediated HLA class I down-regulation. J Immunol 169:3257-3266
20. Gilbert MJ, Riddell SR, Li CR, Greenberg PD (1993) Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J Virol 67:3461-3469
21. Pepperl-Klindworth S, Besold K, Frankenberg N, Farkas M, Kuball J, Theobald M, Plachter B (2006) Cytomegalovirus interleukin-10 expression in infected cells does not impair MHC class I restricted peptide presentation on bystanding antigen-presenting cells. Viral Immunol 19:92-101
22. Gilbert MJ, Riddell SR, Plachter B, Greenberg PD (1996) Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 383:720-722
23. Hobom U, Brune W, Messerle M, Hahn G, Koszinowski UH (2000) Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes. J Virol 74:7720-7729
24. Borysiewicz LK, Hickling JK, Graham S, Sinclair J, Cranage MP, Smith GL, Sissons JG (1988) Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med 168:919-931
25. Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, Cherepnev G, Proesch S, Reinke P, Volk HD, Lehmkuhl H, Kern F (2005) Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201:1031-1036
26. Pahl-Seibert MF, Jülch M, Podlech J, Thomas D, Deegen P, Reddehase MJ, Holtappels R (2005) Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting. J Virol 79:5400-5413
27. Simon CO, Holtappels R, Tervo HM, Böhm V, Däubner T, Oehrlein-Karpi SA, Kühnapfel B, Renzaho A, Strand D, Podlech J, Reddehase MJ, Grzimek NKA (2006) CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J Virol 80:10436-10456
28. Hebart H, Einsele H (2004) Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol 65:432-436
29. Wade JC (2006) Viral infections in patients with hematological malignancies. Hematology Am Soc Hematol Educ Program, pp 368-374
30. Wolff D, Sinzger C, Drescher P, Jahn G, Plachter B (1994) Reduced levels of IE2 gene expression and shutdown of early and late viral genes during latent infection of the glioblastoma cell line U138-MG with selectable recombinants of human cytomegalovirus. Virology 204:101-113
31. Riddell SR, Rabin M, Geballe AP, Britt WJ, Greenberg PD (1991) Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol 146:2795-2804
32. McLaughlin-Taylor E, Pande H, Forman SJ, Tanamachi B, Li CR, Zaia JA, Greenberg PD, Riddell SR (1994) Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 43:103-110
33. Mersseman V, Besold K, Reddehase MJ, Wolfrum U, Strand D, Plachter B, Reyda S (2008) Exogenous introduction of an immunodominant peptide from the non-structural IE1 protein of human cytomegalovirus into the MHC class I presentation pathway by recombinant dense bodies. J Gen Virol 89:369-379
34. Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, Sissons JG (1996) The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70:7569-7579
35. Diamond DJ, York J, Sun JY, Wright CL, Forman SJ (1997) Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90:1751-1767
36. Gallez-Hawkins G, Villacres MC, Li X, Sanborn MC, Lomeli NA, Zaia JA (2003) Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response. J Virol 77:4457-4462
37. Plachter B, Britt WJ, Vornhagen R, Stamminger T, Jahn G (1993) Analysis of proteins encoded by IE-regions 1 and 2 of human cytomegalovirus using monoclonal antibodies generated against recombinant antigens. Virology 193:642-652
38. Pepperl S, Münster J, Mach M, Harris JR, Plachter B (2000) Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J Virol 74:6132-6146